Because melanoma therapies can cause end-organ toxicities (e.g. immune-related adverse events impacting many different organs, and BRAF/MEK inhibitors causing cardiomyopathy), we assessed organ function in relation to systemic therapy. This evidence concerns the gene BRAF and cardiomyopathy.